Nature Communications (Apr 2023)

Identifying high-impact variants and genes in exomes of Ashkenazi Jewish inflammatory bowel disease patients

  • Yiming Wu,
  • Kyle Gettler,
  • Meltem Ece Kars,
  • Mamta Giri,
  • Dalin Li,
  • Cigdem Sevim Bayrak,
  • Peng Zhang,
  • Aayushee Jain,
  • Patrick Maffucci,
  • Ksenija Sabic,
  • Tielman Van Vleck,
  • Girish Nadkarni,
  • Lee A. Denson,
  • Harry Ostrer,
  • Adam P. Levine,
  • Elena R. Schiff,
  • Anthony W. Segal,
  • Subra Kugathasan,
  • Peter D. Stenson,
  • David N. Cooper,
  • L. Philip Schumm,
  • Scott Snapper,
  • Mark J. Daly,
  • Talin Haritunians,
  • Richard H. Duerr,
  • Mark S. Silverberg,
  • John D. Rioux,
  • Steven R. Brant,
  • Dermot P. B. McGovern,
  • Judy H. Cho,
  • Yuval Itan

DOI
https://doi.org/10.1038/s41467-023-37849-3
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Inflammatory bowel disease (IBD) is a group of chronic digestive tract inflammatory conditions whose genetic etiology is still poorly understood. The incidence of IBD is particularly high among Ashkenazi Jews. Here, we identify 8 novel and plausible IBD-causing genes from the exomes of 4453 genetically identified Ashkenazi Jewish IBD cases (1734) and controls (2719). Various biological pathway analyses are performed, along with bulk and single-cell RNA sequencing, to demonstrate the likely physiological relatedness of the novel genes to IBD. Importantly, we demonstrate that the rare and high impact genetic architecture of Ashkenazi Jewish adult IBD displays significant overlap with very early onset-IBD genetics. Moreover, by performing biobank phenome-wide analyses, we find that IBD genes have pleiotropic effects that involve other immune responses. Finally, we show that polygenic risk score analyses based on genome-wide high impact variants have high power to predict IBD susceptibility.